Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I/II Open-label Randomized Multicenter Trial to Assess Immunogenicity and Safety of 4 Prime-boost Combinations of HIV Vaccine Candidates (MVA HIV-B/ LIPO-5; LIPO-5/MVA HIV-B; GTU®-MultiHIV B / LIPO-5; GTU®-MultiHIV B/MVA HIV-B) in Healthy Volunteers at Low Risk of HIV Infection

Trial Profile

Phase I/II Open-label Randomized Multicenter Trial to Assess Immunogenicity and Safety of 4 Prime-boost Combinations of HIV Vaccine Candidates (MVA HIV-B/ LIPO-5; LIPO-5/MVA HIV-B; GTU®-MultiHIV B / LIPO-5; GTU®-MultiHIV B/MVA HIV-B) in Healthy Volunteers at Low Risk of HIV Infection

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 29 Aug 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Anti-HIV lipopeptide vaccine (Primary) ; HIV DNA vaccine (Primary) ; HIV DNA vaccine (Primary) ; MVA HIV vaccine (Primary)
  • Indications HIV infections
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms ANRS/INSERM VRI01; VRI01
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 29 Aug 2017 New trial record
    • 26 Jul 2017 Primary endpoint (Proportion of IFN--ELISPOT responders at Wk30, aiming to discard strategies with 50% responders (M2L2, L2M2, D3L2 group)) has not been met as per the results presented at the 9th International AIDS Society Conference on HIV Science.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top